Boehringer, Lilly win US approval of Tradjenta in Type II diabetes
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim and its partner Lilly gained US approval of their oral dipeptidyl peptidase-4 (DPP-4) inhibitor Tradjenta (linagliptin) as a treatment along with diet and exercise to lower glucose in adults with Type II diabetes.